MCL Literature Feed

This retrospective analysis evaluates transplant outcomes in relapsed/refractory MCL after ibrutinib failure, identifying risk factors to guide patient selection for this intensive consolidation therapy.

This review contextualizes MCL-approved BTK inhibitors by summarizing their distinct covalent and non-covalent binding mechanisms, which underlie differences in efficacy, toxicity, and overcoming resistance.

This first real-world analysis of ASCT for MCL in Argentina confirms its efficacy but identifies blastoid variant, age ≥55, and high comorbidities as independent predictors of poor survival.

This large, real-world study demonstrates that any disease progression, even occurring more than 6 years after initial therapy, significantly worsens overall survival in mantle cell lymphoma.

This comprehensive review synthesizes emerging biomarkers beyond standard prognosticators, including MRD, ctDNA, and advanced imaging, to better guide personalized treatment in the targeted therapy era.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

This review outlines evidence for sequencing BTKis, CAR-T, and bispecifics in relapsed/refractory MCL, a growing challenge as targeted therapies are increasingly used in the frontline setting.

This review describes the clinical presentation, diagnosis, and management of mantle cell lymphoma involving the gastrointestinal tract, a common site of extranodal disease requiring specific diagnostic consideration.

The lymph node microenvironment silences the pro-apoptotic protein BIM via a CD40/PI3K/FOXO1 axis, driving broad drug resistance that can be overcome by bispecific T-cell engager immunotherapy.

An AI-based platform provides more objective and reproducible immunohistochemistry quantification than manual interpretation, improving the diagnostic accuracy in differentiating MCL from CLL/SLL.

This UK real-world study shows chemotherapy bridging before brexu-cel yields higher responses than targeted therapy but causes more toxicity and early mortality without improving post-CAR-T survival.

Frontline zanubrutinib-rituximab induction achieved an 88% complete response rate, enabling a shortened R-DHAOx consolidation, offering a highly effective, chemotherapy-de-escalation strategy for newly diagnosed MCL.

High serum sTNFR2 at diagnosis is a strong prognostic biomarker for inferior overall survival in MCL, implicating the tumor microenvironment and suggesting a new therapeutic target.

This study identifies the SOX11-UHRF1 axis as a new therapeutic target in MCL, demonstrating that the UHRF1 inhibitor CM272 effectively suppresses tumor growth in preclinical models.

Brexucabtagene autoleucel demonstrates high efficacy (91% ORR, 73% CR) in BTKi-naive relapsed/refractory MCL, supporting its use as an effective option before BTKi failure in high-risk patients.

A novel single-cell technique, LiP-Seq, identified IFITM2 upregulation in rare persistent MCL cells post-CAR-T, revealing a new mechanism of immune evasion and a potential therapeutic target.

An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.

The novel BCL-2 inhibitor lisaftoclax demonstrated a 50% overall response rate and manageable safety in a phase 1 trial of Chinese patients with relapsed/refractory MCL.

Absence of CD38 expression in conventional nodal MCL strongly correlates with TP53 inactivation and a distinct genetic profile, identifying a high-risk subgroup via routine flow cytometry.

This German real-world study (2015-2020) reveals rising MCL incidence and poor outcomes, highlighting a dismal median OS of 3.0 months after cBTKi discontinuation, underscoring a critical unmet need.

Dual inhibition of anti-apoptotic proteins BIRC5 and MCL-1 is a novel preclinical strategy to overcome drug resistance in mantle cell lymphoma, offering a potential new therapeutic avenue.

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

The NAMPT inhibitor KPT-9274 sensitizes TP53-mutated MCL to alkylating chemotherapy by disrupting the DNA damage response, offering a novel combination strategy for this high-risk, chemo-resistant population.

A family history of hematological malignancy is associated with inferior event-free survival in mantle cell lymphoma, suggesting it may be a novel adverse prognostic factor.

Adding ibrutinib to intensive frontline immunochemotherapy for newly diagnosed, fit MCL patients aims to deepen responses and improve outcomes, often as induction before transplant consolidation.

Preclinical data shows that inhibiting the cell cycle regulator CDC20 suppresses MCL growth by downregulating the PI3K/AKT pathway, identifying CDC20 as a novel therapeutic target.

Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.

This Chinese real-world study characterizes the clinical features and poor prognosis of blastoid/pleomorphic MCL, providing data to help risk-stratify and manage this aggressive subtype.